There’s still some investor skittishness about the possibility of US drug-pricing legislation, which is affecting the valuations of big pharma/big biotech companies, especially those with a large exposure to Medicare.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.